Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo and SAbR in metastatic clear cell renal cell carcinoma
NCT02781506Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2016
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by UT Southwestern Medical Center. Primary endpoint: Response Rate at 3 years. Started Jun 2016; status: terminated.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02781506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781506.